Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verdant: ARGX-121 in Primary IgA Nephropathy
NCT07773727Phase 2Recruiting
- Sponsor
- argenx
- Start
- Nov 2026
- Primary completion
- Oct 2029
- Countries
- 2
01
Overview
A Phase 2 trial of ARGX-121 in immunoglobulin A nephropathy (IgAN), sponsored by argenx. Started Nov 2026; status: recruiting.
02
Drugs
ARGX-121
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07773727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07773727.